Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Combination with Chemotherapy in Pediatric Patients with Recurrent or Refractory Solid Tumors
NCT03709680Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2019
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of palbociclib in solid tumor, Ewing sarcoma, malignant rhabdoid tumor (MRT), rhabdomyosarcoma (RMS), neuroblastoma, sponsored by Pfizer. Started May 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
solid tumorEwing sarcomamalignant rhabdoid tumor (MRT)rhabdomyosarcoma (RMS)neuroblastoma
Beyond the preview
Go deeper on NCT03709680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709680.